Factors Associated With Immune Checkpoint Inhibitor-Related Myocarditis

Yoshito Zamami; Takahiro Niimura; Naoto Okada; Toshihiro Koyama; Keijo Fukushima; Yuki Izawa-Ishizawa; Keisuke Ishizawa

doi:10.1001/jamaoncol.2019.3113

Factors Associated With Immune Checkpoint Inhibitor-Related Myocarditis

JAMA Oncol. 2019 Nov 1;5(11):1635-1637. doi: 10.1001/jamaoncol.2019.3113.

Authors

Yoshito Zamami^{1

2}, Takahiro Niimura¹, Naoto Okada², Toshihiro Koyama³, Keijo Fukushima⁴, Yuki Izawa-Ishizawa⁵, Keisuke Ishizawa^{1

2}

Affiliations

¹ Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
² Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
³ Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
⁴ Department of Pharmacology for Life Sciences, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
⁵ AWA Support Center, Tokushima University, Tokushima, Japan.

Abstract

This analysis investigates risk factors for immune checkpoint inhibitor–related myocarditis using a large pool of data gathered from the US Food and Drug Administration Adverse Event Reporting System database.